Pfizer announced the discontinuation of its experimental daily weight-loss pill, danuglipron, after a trial patient experienced a potential drug-induced liver injury. The liver enzymes of the patient recovered rapidly after stopping the medication.
This decision marks a significant setback for Pfizer in its efforts to enter the booming GLP-1 obesity drug market, which analysts project could be worth over $150 billion by the early 2030s. This is not the first setback for danuglipron, as Pfizer previously discontinued a twice-daily version due to tolerability issues.
Despite the discontinuation, Pfizer stated it is still developing other weight-loss drugs, including an oral GIPER antagonist and another once-daily oral GLP-1 in earlier development stages. The company remains committed to evaluating and advancing promising programs in this therapeutic area, but the exit of danuglipron impacts its near-term competitive position.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.